1	Peripheral monocyte transcriptomics associated with immune checkpoint
2	blockade outcomes in metastatic melanoma
3	Rosalin A Cooper ^{1,2,3} , Chelsea A Taylor ^{1,2} , Robert A Watson ^{1,2,4} , Orion Tong ^{1,2} , Isar Nassiri ^{1,2} , Piyush Kumar
4	Sharma ^{1,2} , Martin Little ^{1,2,4} , Weiyu Ye ^{1,4} , Surya Koturan ^{1,2} , Sara Danielli ^{1,2} , Mark Middleton ^{1,2,4} , Benjamin P
5	Fairfax ^{1,2,4}
6	1. MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
7	2. Department of Oncology, University of Oxford, Oxford, UK
8	3. Department of Cellular Pathology, John Radcliffe Hospital, Oxford University Hospitals, Oxford, UK
9	4. Cancer and Haematology Centre, Oxford University Hospitals, Oxford, UK
10	ABSTRACT: Clinical responses to immune checkpoint blockade (ICB) for metastatic melanoma
11	(MM) are variable, with patients frequently developing immune related adverse events (irAEs).
12	The role played by myeloid populations in modulating responses to ICB remains poorly defined.
13	We explored the effect of MM and the response to ICB across a cohort of patients with MM
14	(n=116) and healthy donors (n=45) using bulk and single cell RNA-seq, and flow cytometry.
15	Monocytes from patients with MM exhibit highly dysregulated baseline transcriptional profiles,
16	whilst ICB treatment elicits induction of interferon signaling, MHC class II antigen presentation
17	and CXCR3 ligand expression. Although both combination (cICB - anti-PD-1 and anti-CTLA)
18	and single-agent (sICB - anti-PD1) ICB therapy modulates a shared set of genes, cICB displays a
19	markedly greater magnitude of transcriptional effect. Notably, we find increased baseline
20	monocyte counts correlate with a monocyte proliferation signature and risk of early death, whilst
21	a gene-signature corresponding to a subset of platelet-binding classical monocytes conversely
22	associates with improved outcome. This work demonstrates a central role for monocytes in the
23	modulation of treatment response to ICB, providing insights into inter-individual variation in
24	immune responses to ICB and further highlighting the multifarious immunological consequences
25	of ICB treatment.

26

27 Main text

Immune checkpoint blockade (ICB) with single-agent anti-PD1 (sICB) or combination anti PD-28 29 1/anti-CTLA4 (cICB) monoclonal antibodies has transformed the clinical outlook for patients with metastatic melanoma (MM)¹. However, clinical responses are variable and many patients develop 30 immune-related adverse effects (irAEs)^{2,3}. Whilst the relationship between peripheral CD8⁺ T cell 31 characteristics and clinical response of MM to ICB therapy is well described^{4,5}, myeloid responses 32 to ICB remain poorly defined. Existing work suggests that the circulating monocyte population 33 can modulate response to ICB, with an expanded monocyte population typically associated with 34 impaired clinical response to anti-PD1 therapy in both MM⁶ and non-small cell lung cancer 35 36 (NSCLC)⁷. Monocytes are conventionally categorised into three subsets: CD14⁺CD16⁻ classical 37 monocytes, CD14⁺CD16⁺ intermediate monocytes and CD14^{dim}CD16⁺ non-classical monocytes⁸. In MM, small cohort studies have described relationships between monocyte subset counts to 38 response to both anti-PD1 and anti-CTLA4 treatment^{9,10}. There has been limited analysis of the 39 impact of standard-of-care combination anti-CTLA-4/anti-PD-1 treatment however, whilst the 40 impact of ICB on monocyte gene expression and relationships with clinical outcomes are similarly 41 unexplored. 42

We hypothesised that transcriptomic analysis of peripheral monocytes may provide prognostic information and novel insights ICB-treatment response in patients with MM. We assessed monocyte responses to ICB in isolated cells using bulk RNA-sequencing (RNA-seq) across 116 individuals from a cohort of MM patients receiving ICB as well as samples from 45 healthy controls. We find MM is associated with distinct pro-inflammatory changes in monocyte gene-expression, the extent of these correlating with baseline monocyte count and having prognostic value. Treatment with either cICB or sICB therapies evokes shared patterns of gene

expression but no consistent change in counts of conventional subsets. We further characterised heterogeneity in peripheral monocyte subsets in MM with scRNA-seq and flow cytometry, noting relationships with clinical outcome, observing positive outcomes to be associated with an expanded platelet binding subset whereas monocyte proliferation is associated with risk of early death.

55

56 **RESULTS**

57 <u>Circulating monocytes in patients with metastatic melanoma have a distinct transcriptomic</u> 58 <u>profile</u>

59 To identify MM-associated signatures in circulating monocytes at baseline, we performed 60 differential gene expression (DGE) across monocytes from patients with MM versus healthy 61 donors (HD) (C1 n = 114 samples; HD n = 45 samples). This identified 1,774 significantly differentially regulated transcripts in patient derived monocytes (P_{adi} <0.05; Figure 1A, 62 Supplementary Table 1), including 871 upregulated, and 903 suppressed. Of note, genes encoding 63 the chemokine receptors CXCR1 and CXCR2, which bind to pro-inflammatory cytokine and 64 65 neutrophil chemoattractant IL-8, implicating pathways previously found to be associated with a less favorable response to ICB¹², were markedly upregulated in MM patients (Figure 1B). 66 Interrogation of the Gene Ontology Biological Processes (GOBP) database¹³ identified key 67 expression pathways enriched in patient samples including chemotaxis (GO:0006935, Padj = 68 0.0014; GO:0060326, $P_{adj} = 0.0096$), neutrophil degranulation (GO:0043312, $P_{adj} = 5.4 \times 10^{-14}$), 69 response to lipopolysaccharide (GO:0032496, $P_{adj} = 0.00027$), and vascular endothelial growth 70 71 factor (VEGF) signaling (GO:0048010, $P_{adj} = 0.02$) (Figure 1C, Supplementary Table 2). Given increasing monocyte count is associated with poorer clinical outcome in melanoma⁶ and non-small 72 73 cell lung cancer (NSCLC)⁷, we examined the relationship between baseline monocyte gene

74 expression and pre-treatment hospital measured monocyte count. Strikingly, increasing monocyte count was associated with markedly divergent expression profile, with 1,344 transcripts associated 75 with pre-treatment monocyte count (88 C1 samples, Padi<0.05; Figure 1D, Supplementary Table 76 77 3), of which 694 transcripts were positively associated with count, the most significant being FAM20A, encoding a pseudokinase with putative roles in haematopoiesis¹⁴ (Figure 1E). 78 Conversely, increasing counts were negatively associated with 650 transcripts, most significantly 79 *IMPDH2*, encoding a gene involved in purine metabolism in response to hematopoietic stress¹⁵ 80 (Figure 1E). Pathways positively correlated with monocyte count included neutrophil 81 degranulation (GO:0043312, $P_{adj} = 4.6 \times 10^{-20}$), as well as heterotypic cell-cell adhesion 82 (GO:0034113, $P_{adj} = 2.5 \times 10^{-3}$) and VEGF signaling (GO:0048010, $P_{adj} = 2.9 \times 10^{-3}$), whilst 83 suppressed pathways were mainly involved in rRNA processing (GO:0006364, $P_{adj} = 5.7 \times 10^{-23}$) 84 and DNA replication (GO:0006260, $P_{adj} = 7.0x10^{-8}$) (Supplementary Table 4). Of particular 85 significance to cancer immunology was the negative association of IFNG regulated MHC class II 86 gene expression, crucial in antigen presentation, including HLA-DRA (Padj = 0.0005), HLA-DMA 87 $(P_{adj} = 0.0063)$, HLA-DPA1 $(P_{adj} = 0.00057)$ and HLA-DPB1 $(P_{adj} = 0.0010)$ with peripheral 88 89 monocyte count (Supplementary Table 3). In keeping with this, transcripts anti-correlated with monocyte count were enriched for pathways including antigen presentation via MHC class II 90 (GO:0019886, $P_{adj} = 0.014$) and T cell co-stimulation (GO:0031295, $P_{adj} = 0.041$) (Supplementary 91 92 Table 4). Thus, an expanding circulating monocyte compartment is characterized by polarisation 93 towards an immature, mitotically active 'classical monocyte' phenotype with predisposition towards heterotypic cell adhesion, VEGF mediated angiogenesis and reduced antigen presentation 94 95 function.

96

97 ICB treatment modulates circulating monocyte gene expression

98 To address the impact of ICB on monocytes, differential expression analysis between baseline 99 (pre-treatment, 'C1') and post-treatment ('C2') samples (n = 96 patients), controlling for age, sex and treatment type (sICB/cICB) was performed in bulk monocyte RNA-seq data. This identified 100 101 a total of 1,067 significantly differentially modulated transcripts with ICB (758 induced, and 309 downregulated; P_{adi}< 0.05) (Figure 2A & 2C, Supplementary Table 5). ICB treatment robustly 102 induced type I and II interferon signaling (Figure 2A, Supplementary Table 5) including JAK-103 104 STAT pathway members STAT1 ($P_{adj} = 2.0 \times 10^{-7}$), STAT2 ($P_{adj} = 3.0 \times 10^{-4}$), and JAK2 ($P_{adj} = 1.4 \times 10^{-7}$) ⁶). The CXCL3 ligands CXCL9 ($P_{adj} = 8.1 \times 10^{-9}$), CXCL10 ($P_{adj} = 1.0 \times 10^{-8}$) and CXCL11 ($P_{adj} = 1.0 \times 10^{-8}$) 105 4.1x10⁻⁶) were similarly induced. These IFN- γ induced transcripts are involved in CXCR3-106 107 dependent immune cell chemotaxis and T_H1 polarisation^{16,17} and are associated with development of irAEs^{18,19}. Similarly induced were transcripts encoding the classical complement proteins C1QA 108 109 $(P_{adj} = 3.6 \times 10^{-5}), C1QB (P_{adj} = 9.8 \times 10^{-5}) \text{ and } C1QC (P_{adj} = 4.4 \times 10^{-5}); MHC class II molecules$ including HLA-DRA ($P_{adj} = 1.6 \times 10^{-4}$) and HLA-DPB1 ($P_{adj} = 1.9 \times 10^{-5}$), as was CD274 ($P_{adj} =$ 110 111 2.8x10⁻⁹), encoding PD-L1^{20,21} (Figure 2A, Supplementary Table 5). Correspondingly, ICB induced transcripts were enriched across multiple pathways including IFN-y-signaling 112 (GO:0060333, $P_{adj} = 2.5 \times 10^{-21}$), type I interferon-mediated signaling (GO:0060337, $P_{adj} = 9.8 \times 10^{-21}$) 113 ¹²), antigen presentation via MHC class I (GO:0002479, Padj = 2.5×10^{-21}) and class II 114 (GO:0019886, $P_{adj} = 0.0069$), and T cell co-stimulation (GO:0031295, $P_{adj} = 1.5 \times 10^{-4}$) (Figure 2D, 115 Supplementary Table 6). Expression of signaling pathways including tumour necrosis factor 116 (TNF) (GO:0033209, $P_{adj} = 2.5 \times 10^{-10}$) and NF κ B signaling (GO:0043123, $P_{adj} = 5.3 \times 10^{-3}$) were 117 also enriched in monocytes following ICB (Figure 2D, Supplementary Table 6). 118 119 Comparative analysis of monocyte responses to cICB versus sICB demonstrated that, as per CD8

T cells⁴, cICB was associated with a greater magnitude of transcriptional modulation, with 2,777 transcripts differentially expressed with cICB (pairwise analysis, n=51 patients) but only 85

122 following sICB (pairwise analysis, n=45 patients) (Figure 2B, 2C, Supplementary Figure 1, 123 Supplementary Tables 7 & 8). There was near complete concordance of the transcripts modulated by cICB versus sICB (80/85 transcripts) and sICB and cICB demonstrated consistent shared 124 125 direction of effect, but greater magnitude of transcriptional modulation with cICB (Figure 2C, 2E). A total of 352 transcripts (240 induced, 112 suppressed) were preferentially regulated in 126 monocytes with cICB compared to sICB. Preferentially cICB induced transcripts included CD274 127 $(P_{adj} = 0.0033), CXCL10 (P_{adj} = 6.3 \times 10^{-3}), CXCL11 (P_{adj} = 0.042), and C1QC (P_{adj} = 0.019)$ 128 (Supplementary Table 9) and corresponding pathway analysis of these genes again highlighted 129 enrichment of type I IFN and IFN-y-related signaling, JAK-STAT and T cell receptor signaling 130 131 (Figure 2F, Supplementary Table 10). This suggests that, as with CD8⁺ T cells⁴, cICB is associated 132 with a qualitatively similar but quantitively greater transcriptional effect on peripheral monocytes. 133

. . .

134 <u>Peripheral monocyte transcriptomic profiles predict clinical outcome</u>

We then identified monocyte-expressed markers of clinical response by performing differential 135 expression analysis of bulk RNA-seq data with clinical outcome parameters. Clinical parameters 136 137 including risk of death at three, six and twelve months after date of first treatment, and progression at six-months were used to dichotomise patients, with differential expression analysis controlled 138 for age, sex and, where applicable, treatment type and cycle. We found a monocyte cycling 139 140 signature characterised by expression of proliferation index marker MKI67 to be associated with 141 death at all three time points (Figure 3A-C, Supplementary Tables 11-13) with 314, 239 and 444 transcripts associated with death at three, six and twelve months respectively (controlling for age, 142 143 sex, treatment status and type across 114 C1 and 98 C2 patient samples, P_{adj}<0.05) (Figure 3A-C, Supplementary Tables 11-13). Transcripts across all time points positively correlated with death 144 were enriched for pathways associated with the monocyte MM-associated expression signature we 145

146 describe above, including neutrophil degranulation (GO:0043312), platelet degranulation 147 (GO:0002576) and response to LPS (GO:0032496) (Figure 3E, Supplementary Table 14-16). Strikingly, when we explored this by treatment status, risk of death was primarily related to pre-148 149 treatment samples (Supplementary Figure 2, Supplementary Table 17A-C). We also found 269 150 transcripts associated with progression at six months (113 C1 samples and 98 C2 controlling for treatment type, status, age and sex, P_{adi}<0.05) (Figure 3D, Supplementary Table 18A) which were 151 enrichment for pathways including angiogenesis (GO:0001525) (Supplementary Table 18B). 152 These observations indicate previously undescribed mechanisms through which the prognostic 153 154 effects of peripheral monocytes and elevated counts are mediated.

155

156 Dissecting heterogeneity in monocyte subgroup responses to ICB

157 Monocytes are heterogeneous in composition but are conventionally categorized into three subsets: CD14⁺CD16⁻ classical monocytes, exhibiting prominent chemotactic properties, CD14^{dim}CD16⁺ 158 non-classical monocytes implicated in antibody dependent cellular cytotoxicity (ADCC)²³; and 159 CD14⁺CD16⁺ intermediate monocytes, characterized by prominent MHC class II expression²⁴. We 160 161 used flow-cytometry to explore monocyte populations pre and post ICB, finding no significant change in any subset size with treatment (n = 53 paired samples) (Figure 4A), this observation 162 remaining when performing sICB and cICB specific analysis (Supplementary Figure 3). Notably, 163 164 survival analysis showed that a larger proportion of cytometry-identified non-classical monocytes at both baseline and following treatment was associated with prolonged overall survival (OS) (at 165 baseline C1 P = 0.0079; post-treatment C2, P = 0.0016, log-rank tests) and extended progression 166 167 free survival (PFS) (P = 0.014 at C1, post-treatment C2: P = 0.02, log-rank test) (Figure 4B). Conversely, consistent with the hospital blood monocyte count, increasing monocyte proportion 168 as a total of peripheral blood mononuclear cells (PBMCs) pre-treatment was associated with 169

reduced OS (pre-treatment, P= 0.014, log-rank test), and post-ICB reduced PFS and OS (posttreatment PFS P = 0.028; OS, P= 0.031, log rank test) (Figure 4C). In keeping with previous studies²⁵, a higher lymphocyte to monocyte ratio (LMR) at baseline was associated with extended OS (p = 0.035, log-rank) (Supplementary Figure 3).

174

175 Characterising peripheral monocytes with scRNA-seq

176 To further characterize the predictive role of monocyte subsets, we performed scRNA-seq of monocytes from peripheral blood both pre- and post-ICB treatment from eight patients with MM, 177 as well as three healthy donors (Supplementary Figure 4). Unsupervised clustering of cells across 178 179 all conditions was performed to a high resolution i.e. 'overclustering', and comparison with 180 publicly available annotated expression datasets using *SingleR* (Supplementary Figure 4) was 181 performed. Monocyte groups present across all conditions/patients were selected for downstream analysis (Supplementary Figure 5) and a total of 22,116 cells were analysed. Two main monocyte 182 subsets were identified: those aligned to a classical monocyte annotation, and those annotated as 183 an intermediate/non-classical FCGR3A-expressing 'CD16⁺ monocyte' group (Figure 5A, 184 Supplementary Figure 5). The large classical-like monocyte cluster was characterised by markers 185 including CD14 (P_{adi}= 5.3x10⁻²⁵¹), and genes involved in adhesion and migration including 186 $CLEC4E^{29}$ (P_{adj}= 6.6x10⁻⁶⁷), $VCAM^{30}$ (P_{adj} < 1x10⁻³⁰⁰), $CCR2^{29,31}$ (P_{adj}= 2.0x10⁻⁶⁶) and $SELL^{29}$ (P_{adj}. 187 $= 1.0 \times 10^{-94}$) (Supplementary Figure 6, Supplementary Table 20). Pathway enrichment included 188 response to lipopolysaccharide (GO:0032496) and response to wounding and wound healing 189 (GO:0009611, GO:0042060) (Supplementary Figure 6, Supplementary Table 22). CD16+ 190 monocytes were defined by expression of FCGR3A ($P_{adj} < 1x10^{-300}$), TNF ($P_{adj} = 6.2x10^{-52}$), 191 192 classical complement genes CIQA (P_{adj}= 2.2x10⁻¹⁶⁷), CIQB (P_{adj}= 1.51qx10⁻¹¹⁶), and CIQC (P_{adj}= 4.7x10⁻⁸³) and interferon-induced genes including *IFITM1* (Padj= 5.8x10⁻¹⁸¹), *IFIT2* (Padj= 2.2x10⁻¹⁸¹) 193

²²), and *IFIT3* (P_{adj}= 7.3x10⁻⁷³) (Supplementary Table 20), these genes being enriched for T cell
 co-stimulation (GO:0031295), T cell receptor signaling (GO:0050852), and antigen processing
 and presentation via MHC-class II pathways (GO:0019886) (Supplementary Table 22) pathways.

We did not identify a distinct intermediate monocyte population on high-level unsupervised 198 clustering, however unsupervised clustering of the large classical monocyte compartment revealed 199 further heterogeneity within it. We found the classical monocyte compartment could be further 200 divided into four distinct sub-clusters: 'Classical1' characterised by high expression of alarmin 201 complex genes S100A8/A9; 'Classical2' with high expression of CD14 and EGR1, a key inhibitory 202 regulator of myeloid populations²⁸; 'Classical3' with robust expression of an IFN-response 203 204 associated signature including GBP1, GBP2, and STAT1; and 'Classical4' which had a distinct 205 monocyte-platelet aggregate (MPA)-like classical profile with high expression of plateletassociated genes including PPBP ($P_{adi} = 9.5 \times 10^{-159}$) which encodes chemokine and 206 CXCR1/CXCR2 ligand CXCL7 in activated platelets²⁶, and GP9 ($P_{adi} = 2.3 \times 10^{-38}$), a von 207 Willebrand factor receptor required for clotting²⁷ (Figure 5A & 5B, Supplementary Table 19). 208 Pathway enrichment analysis of group-defining markers demonstrated overlap between groups, 209 but Classical was characterised by enrichment of antimicrobial humoral response pathway, 210 Classical2 for phagocytosis, Classical3 for defense response to virus, antigen processing via MHC 211 class II and T cell co-stimulation (Figure 5C, Supplementary Table 21) whilst Classical4 was 212 213 enriched for platelet activation and blood coagulation pathways (Figure 5C, Supplementary Table 21). Notably, although power to detect ICB related subset size changes was limited, we found no 214 215 significant change in the proportion of classical, $CD16^+$ or classical subgroups (Classical₁ – Classical₄) with ICB (Supplementary Figure 7), in keeping with flow-cytometry observations. 216

217

We performed analysis of monocytes according to expression of gene sets consisting of the most 218 219 significantly associated transcripts of a candidate 'hub gene' (Supplementary Figure 8). Both antigen-presentation and complement module scores comprised genes characteristic of non-220 221 classical monocytes such as FCGR3A, CDKN1C and MHC Class II genes (Supplementary Tables 23-28). The chemotaxis score comprised a classical expression signature. CD16⁺ monocytes had 222 higher expression antigen-presentation, complement production, and IFN signaling modules, 223 whilst classical monocytes exhibited higher expression of chemotaxis-associated gene modules 224 (Figure 5D). Expression module scoring revealed a continuum of activation states across the 225 classical subgroups, with Classical1 and Classical2 exhibiting low complement and antigen 226 227 presenting expression module scores, and Classical3 expressing higher expression of these modules (Figure 5D). 228

229

Having defined monocyte transcriptional heterogeneity with scRNA-seq in a subset of patients, 230 we determined to explore the clinical correlates of the identified subset associated expression 231 signatures across the full cohort. Intriguingly, we found that expression above the median of the 232 MPA expression signature (Classical4) at baseline was associated with improved clinical outcomes 233 to ICB with significant associations to PFS (p = 0.011, log-rank median PFS low MPA: 5.5 mnths 234 (95% CI 15.2 - 30.2), median PFS high MPA: 35.1 mnths (95% CI 28.1 - 43.1) and OS (P = 235 0.025, log-rank, mean OS low MPA: 25.0 mnths (95% CI 28.1 - 43.1), median OS high MPA: 236 237 53.3 mnths (95% CI 38.4 – 52.3)) (Figure 5E).

238

239 **DISCUSSION**

Cancer has been associated with altered transcriptional profiles in monocytes with upregulation of
 chemotaxis pathways^{32–35}, impaired cytotoxicity³⁶, polarisation towards an immature phenotype³⁷

and altered metabolic pathways^{9,32}. Here we show in the analysis of a large patient cohort that MM 242 likewise has distinct effects on monocyte expression profiles, with induction of chemotaxis, 243 adhesion and angiogenesis-associated pathways. An elevated monocyte count has been associated 244 with poor prognosis across cancer types^{38–41}. For the first time we show that a raised monocyte 245 246 count is accompanied by profound changes in monocyte transcriptional profiles, indicating mechanisms through which the prognostic effects of elevated monocytosis may be mediated. 247 Specifically, as well as increased expression of mitotic factors, there is upregulated VEGF 248 expression, indicating the emergence of a cycling, immature pro-angiogenic 'classical-type' 249 250 expression profile.

251 We provide novel insights into the effects of ICB treatment on immunity. Using bulk monocyte 252 RNA-seq data from a large MM cohort we demonstrate that ICB promotes a monocyte transcriptional profile in keeping with a T cell costimulatory phenotype, with upregulation of 253 antigen presentation via MHC class II pathways, classical complement and pro-inflammatory 254 cytokines. Notably, CXCL9, CXCL10 and CXCL11 are all robustly upregulated in monocytes by 255 ICB. The CXCL9-11/CXCR3 axis is implicated in immune migration and the development of Th1 256 cells¹⁷ whilst the myeloid CXCR3-CXCL9/10/11 axis has a key role in modulating CD8⁺ T cell 257 responses in the context of ICB⁴². Induction of this axis in macrophages following cICB is also 258 described, with CXCL9-expressing macrophages required for CD8⁺ T cell infiltration and for 259 effective clinical response⁴³. Here we extend these observations from murine tumour based 260 myeloid cells, demonstrating activation of this axis in circulating monocytes in patients, indicating 261 that monocytes may play an early role in modulating peripheral CD8⁺ T cell recruitment. Notably, 262 263 as in CD8⁺ T cells, although it is qualitatively concordant the magnitude of transcriptional response is far greater with cICB versus sICB⁴. Given the dosing of nivolumab in cICB is 1mg/kg as 264 opposed to fixed monthly dosing of 480mg, patients typically receive much less anti-PD-1 265

treatment at the outset of this regimen. This marked divergence in transcriptional responses between sICB and cICB attests to a highly significant synergistic effect of the addition of ipilimumab and may reflect the greater propensity for cICB to both induce irAEs as well as longterm durable disease control. Interestingly, despite marked transcriptional changes, consistent shifts in the size of monocyte proportion or classical and non-classical populations were not seen in response to ICB in our dataset, potentially indicating a peripheral 'steady state' following ICB in early post-treatment timepoints.

273

Expansion of circulating monocytes is associated with a less favourable clinical outcome across 274 different malignancies^{44–47}. In keeping with previous reported associations, we find that a smaller 275 276 monocyte population both before and after ICB is associated with better clinical outcome, as is a higher pre-treatment lymphocyte to monocyte ratio. However, intra-compartmental heterogeneity, 277 polarization and activity also appears significant. We show that a monocyte cycling signature 278 (inferred by MKI67 expression) with enrichment of MM-associated 'classical-type' signature at 279 baseline is predictive of early death. We also explore the role of monocyte subsets in this context. 280 A larger non-classical monocyte subset, both at baseline and following treatment, is associated 281 with a more favourable prognosis. This suggests that response to ICB is determined in part by 282 baseline characteristics in circulating monocytes, with an immature classical 'cycling' signature a 283 284 poor prognostic signature, and a non-classical population associated with more favourable response to ICB. This may be underpinned by the T cell co-stimulatory phenotype and effects of 285 pro-inflammatory non-classical monocytes. 286

We use scRNA-seq to dissect the roles of monocyte subsets in predicting response to ICB. Whilst there are three conventionally recognised monocyte subsets, scRNA-seq studies are notable for the discrepancy and variety of described subsets^{48–51}. However, in keeping with most studies, we

12

identify a large classical subset, and smaller CD16+ subset. We isolated monocytes for scRNA-290 291 seq with magnetic bead sorting using CD14 antibodies, and this potentially enriched for classical monocytes, allowing us to describe the transcriptional heterogeneity within this compartment. In 292 293 keeping with this, our unsupervised clustering of scRNA-seq data identifies four sub-clusters within the classical subset. Notably, we observe one, Classical4, with expression profiles 294 consistent with an MPA-associated signature. Applying the expression signature of this subset 295 cohort-wide across the bulk monocyte RNAseq data demonstrates that increased pre-treatment 296 expression of this geneset is associated with a more favourable prognosis. Whether this reflects a 297 genuine subset of increasingly reactive monocytes or alternatively, is a proxy marker for anti-298 299 tumour monocyte or platelet activity is unclear and requires analysis in larger single-cell datasets 300 currently being generated. Notably MPA are described across multiple conditions and have been associated with poor prognosis in cardiovascular disease⁵² and COVID-19⁵³. Monocyte-platelet 301 adhesion enhances CD16 expression and promotes a pro-inflammatory phenotype in circulating 302 monocytes⁵⁴. In the context of cancer this monocyte 'stickiness' at baseline may predict propensity 303 to polarisation towards a pro-inflammatory myeloid response with T cell costimulatory effects. 304

A limitation of this work is the extent to which the changes we observe in monocyte expression in 305 response to ICB therapy reflect ICB induced T cell activation, versus direct modulation of 306 monocytes on T cell activation. Our analyses of CD8⁺ T cells in patients with MM has provided 307 critical insights into how T cell responses and clonal dynamics reflect clinical response to ICB and 308 confirmed the potential role for peripheral immune signatures as clinical predictive biomarkers^{4,5}. 309 Further work to dissect this interaction in larger datasets at single-cell resolution will be key to 310 311 fully understanding the mechanism of immune modulation of ICB treatment across individuals and the relationship with clinical response. Nonetheless, our analysis describes favourable 312 313 associations with clinical outcome of increased counts of non-classical monocyte subsets as

defined by flow-cytometry. Conversely, we find that the increased monocytosis frequently observed in MM is associated with profoundly pro-inflammatory and pro-angiogenic expression profiles of monocytes in this state, with a presumed pro-tumourogenic effect, and indicating a causal role in impaired response to ICB and early death in MM.

318

319 MATERIALS AND METHODS

320 Samples

Peripheral blood samples were obtained from patients >= 18 years old with metastatic melanoma 321 (MM) treated with immune checkpoint blockade (ICB). This included patients treated with 322 323 ipilimumab/nivolumab (anti-CTLA-4/PD-1) combination immune checkpoint blockade (cICB), 324 and with single-agent pembrolizumab or nivolumab (anti-PD-1) immune checkpoint blockade (sICB). All patients provided prior written informed consent for samples to be donated to the 325 Oxford Radcliffe Biobank (Approved by South Central – Oxford C Research Ethics Committee 326 12th April 2019, REC Reference 19/SC/0173 with internal Oxford Centre for Histopathology 327 Research ethical approval, 16/A019, 18/A064) to be used for research. Peripheral blood samples 328 were obtained prior to the first treatment dose (cycle 'C1', day0), and then just before the second 329 dose (cycle 2, C2, day21). ICB treatment regimes were according to standard treatment protocols. 330 For patients receiving cICB this involved administration of ipilimumab and nivolumab every three 331 332 weeks for up to four doses. For patients treated with sICB, pembrolizumab was administered once every three weeks, or every four weeks for nivolumab. Up to 50 ml of peripheral blood was 333 collected per sample in ethylenediaminetetraacetic acid (EDTA) tubes. Control samples were 334 335 obtained from the Oxford biobank after informed written consent was obtained. Samples were collected with local ethical approval (REC 06/Q1605/55). 336

337

338 Clinical Data

Clinical outcome data across the cohort was obtained, including parameters such as progression at six months, time-to-progression, overall survival (OS), progression free survival (PFS) and death status. OS was defined as the time between the start date of ICB treatment to death, whilst PFS was defined as time between the first ICB dose and disease progression according to either death or disease progression on imaging. Clinical outcome data was available for 114 samples at baseline (C1) and 98 post-treatment (C2) samples.

345

346 Bulk RNA Sequencing

Bulk RNA-seq was carried out on CD14⁺ cells from 45 healthy donors, and 116 MM patients 347 348 treated with ICB. Patients receiving adjuvant ICB were excluded from analysis. A total of 114 C1 (day0) and 98 C2 (day21) samples were sequenced, including from 91 patients with paired pre and 349 post treatment data. Bulk RNA-seq libraries were sequenced in three batches. The first RNA cohort 350 was sequenced using 75 bp paired-end sequencing on an Illumina Hiseq-4000 platform. The 351 second cohort was sequenced using the Illumina NovaSeq platform with 150 bp paired-end 352 sequencing. The third batch of samples was run on a NovaSeq6000 platform using 150 bp paired-353 end sequencing. The bulk RNA-seq was performed at the Oxford Genome Centre, Wellcome 354 Centre for Human Genetics. HISAT2⁵⁵ was used to align reads in FASTQ files to the GRCh38/hg38 355 genome build. Adequately mapped reads were identified according to MAPQ score with bamtools. 356 *Picard* was used to remove duplicate reads. *HTseq*⁵⁶ was used to generate read count data. 357

358

359 **Differential expression analysis**

Differential expression analysis of bulk RNA-seq data was carried out using $DESeq2^{11}$. DESEq2was used to normalise read counts. The *ComBat-seq*⁵⁷ package was used to remove the effect of batch sequencing.

For differential expression analysis of transcripts expressed across healthy donors ('HD' or 'C') versus pre-treatment samples, variables including sex and sex were included in the *DESEq2* design argument (i.e. design = \sim sex + age + cycle). Transcripts were filtered and only those with a mean count > 10 were selected for differential expression analysis. Differential expression analysis was performed using a binomial Wald test. The Benjamin-Hochberg (BH) method was used to correct for multiple testing to identify significantly differentially expressed transcripts (P_{adj}<0.05).

To identify transcripts in CD14⁺ cells associated with clinical outcome parameters, differential expression analysis was used, dichotomising clinical outcome data, either into those who had disease progression at six months, versus those who did not progress; and those who died three, six and twelve months after starting ICB treatment, versus those that did not. *DESEq2* was used to perform differential expression analysis, controlling for treatment state and type (sICB or cICB) where applicable, as well as age and sex.

375

376 Pathway enrichment analysis

The *XGR*⁵⁸ package was used for pathway enrichment analysis using interrogation of the GOBP database. Unless otherwise stated, induced/suppressed or positively/negatively associated transcripts were analysed separately.

380

381 scRNA-seq samples

scRNA-seq library preparation and sequencing was performed as previously described^{4,5}. In the
 first batch, CD8⁺ and CD14⁺ cells were isolated from PBMCs from peripheral blood from four

patients treated with ipilimumab/nivolumab combination-immune checkpoint blockade (cICB) and four treated with pembrolizumab single-immune checkpoint blockade (sICB). Samples were obtained before (C1, day0) and after (C2, day21) the first treatment cycle. Healthy donor samples from three individuals were pooled prior to library preparation and sequenced in a second batch.

388

389 scRNA-Seq library preparation

The Chromium 10x platform was used for scRNA-seq library preparation. scRNA-seq data was prepared in two batches. In the first batch, 6000 of both CD8⁺ and CD14⁺ cells were combined3 in suspension (total number 12,000 cells). In the second batch, 2000 CD14⁺ cells from each of three healthy donors were mixed in suspension in a single well. 5' transcriptome processing was performed using the Chromium 10x system. Samples were processed according to standard manufacturer's protocols⁵⁹. This involved initial barcoding with a unique tag, reverse transcription, cDNA amplification and library preparation.

For the first batch, 5' transcriptome library sequencing was performed using a HiSeq platform with 397 75bp paired-end sequencing with a depth of at least 50,000 reads per cell. The healthy donor 398 control samples were sequenced using a NovaSeq 6000 platform with 150 bp paired-end 399 sequencing with a mean sequencing depth of 78,000 reads per cell. The *Cellranger* package was 400 used to process scRNA-seq data⁶⁰. The Cellranger *mkfastq* was used to produce FASTQ files from 401 402 the Illumina BCL files. Cellranger *count* was then applied to each FASTQ file to produce a feature barcoding and gene expression library. Cellranger *mkfastq*, count and aggr were used to combine 403 samples for merged downstream analysis. 404

405

406 scRNA-seq quality control

For quality control (QC), the *scater* package⁶¹ was used to remove outliers, and *scran*⁶² package was used to remove doublets. Cells were then selected based on *CD14* expression, with those cells expressing *CD8A*, *CD3D*, *CD3E*, *CD3G*, *CD56*, *CD19* or *CD20* removed from downstream analysis to remove possible contaminants. QC was then performed by removing cells that had fewer than 300 different features (genes), fewer than 500 UMIs (transcripts) and those whereby more than 20% of expressed genes were mitochondrial. Genes expressed in fewer than five cells were also removed from downstream analysis.

414

415 Clustering analysis

The Seurat⁶³ package in R was used for downstream analysis of the scRNA-seq data. The raw gene 416 expression matrix was normalised and then subject to *FindVariableFeatures* function⁶³. Both 417 untreated and treated samples were merged following normalisation. Integration anchors between 418 MM patient and Healthy donor (Control) data sets were identified using *FindIntegrationAnchors* 419 and integration of the patient and Control datasets was performed with *IntegrateData* function. 420 Data was then scaled, and then a principal component analysis was run using the first 13 421 dimensions. This level of dimensionality was chosen as it was the level at which the variation 422 between consecutive principal components was minimal as seen on an *Elbowplot*. Unsupervised 423 clustering was performing using the *FindClusters* function and the clusters visualised using a 424 425 uniform manifold approximation and projection (UMAP) plot.

The *clustree*⁶⁴ package was used to visualise monocyte clustering trees at resolutions of 0.1, 0.2 0.25, 0.5, 0.75, 1,2 and 3 (at 13 dimensions). To perform annotation of monocyte clusters with published gene sets the *singleR*⁶⁵ package was used to compare the scRNA-seq data to annotated expression datasets including the Human Primary Cell Atlas dataset⁶⁶, MonacoImmune dataset⁶⁷, Immune Cell Expression data set⁶⁸ and scRNA-seq data published by Villani et al⁴⁸. Only groups

found across all conditions and patients were used for downstream analysis. As such, cluster 5 was
removed from downstream analysis as it was present only in patient ID7 post-treatment and in
controls.

434

435 Identification of cluster-defining markers

To identify genes differentially expressed in monocyte cluster the *FindAllMarkers* function was used to find differentially expressed genes between a single subset and the remaining data, selecting only positively expressed transcripts with the default Wilcoxon signed-rank sum test. The logFC threshold was set to -Inf and a method based on Bonferoni adjustment was used to correct for multiple testing.

441

442 Gene expression module scoring

To calculate the phenotype scores (e.g. immaturity, complement, antigen presenting scores), the 443 Seurat AddModuleScore function was utilised to assign a score indicating the average expression 444 of a defined gene set per single cell. The gene sets used for module scoring applied to each cell 445 were identified by selecting the top 50 genes most significantly correlated with hub genes of 446 interest such as CD14, C1QA, and HLA-DR expression. To identify significantly correlated 447 transcripts, Pearsons correlation analysis was performed across all single cells and across Variable 448 feature genes (n=2000) using the *Hmisc* package in R, adjusting for multiple testing using the 449 Holm's method with the *RcmdrMisc* function. Hub genes were selected based on association with 450 a particular phenotype or function. For example, FCGR3A was selected as a hub gene indicative 451 452 of non-classical phenotype.

453

454 Subset scoring in bulk RNA-seq data

We identified the 20 most highly expressed genes identified using *FindAllMarkers* definitive of each monocyte cluster and the geometric mean score of this gene set across each *DESEq2*normalised bulk RNA-seq patient sample was calculated. Association between this expression signature and clinical outcome data was performed using the *survminer* and *survival* packages to perform survival analysis.

460

461 Flow cytometry

462 Following separation, PBMCs were stored in liquid nitrogen in 90% FCS and 10% dimethyl sulfoxide (DMSO). Samples were thawed and then 1×10^{6} PBMCs were placed into a solution of 463 HBSS with 5% FCS on ice. After 30 mins cells were fixed in 2% formaldehyde. Samples were 464 stained using a fixable amine-reactive viability dye (LIVE/DEAD Fixable Near-IR Dead Cell Stain 465 Kit). The appropriate antibodies were added to the sample as outlined below. The flow cytometry 466 was carried out with a LSRII (Becton Dickinson) platform. FlowJo software was used to analyse 467 cells blinded to clinical outcome data. For gating, myeloid cells were identified using FSC-A and 468 SSC-A, excluding doublets. Dead/dying cells were removed via the selection of viability stain 469 negative cells. Monocytes were then selected based on CD14 expression, and then classical, 470 471 intermediate and non-classical monocytes were gated according to relative CD14/CD16 expression. 472

473

Antibody/stain	Fluorochrome	Clone	Dilution	Source
Live/Dead cell stain kit	Near-IR	n/a	1000	ThermoFisher Scientific
CD14	PE/Cy7	M5E2	50	BioLegend

CD16	FITC	3G8	50	BioLegend
------	------	-----	----	-----------

474

475 Survival analysis

The *survminer* and *survival* packages were used to perform survival analysis (exploring association with OS and PFS) and visualise Kaplan-Meier curves. Samples were dichotomised into two subsets according to variable of interest e.g expression score, being above or below the median value. A log-rank test was used to determine statistical significance.

480

481 **Statistical analyses**

All statistical analyses were performed within the R package (v 4.2.2). Plots were created using *ggplot2*. Boxplots demonstrate the upper and lower quartiles, with the line in the middle indicating the median, and Tukey's whiskers indicating the range. Unless otherwise states, a Wilcoxon signed-rank test was used to test for significance.

486

487 Figure 1: Peripheral monocytes exhibit distinct transcriptomic profiles in patients with 488 metastatic melanoma

1A)Volcano plot to show significantly differentially expressed genes between MM patients at baseline ('C1') and healthy donors (HD) (114 C1 samples, 45 healthy controls, DESEq2 analysis controlling for age and sex ($P_{adj} < 0.05$). B) Boxplot to show log2(CXCR1) and log2(CXCR2) expression in monocytes in MM patients at baseline (C1) versus healthy donors (HD). C) Dot plot to show key enriched and suppressed GOBP pathways in monocytes in MM patients versus healthy controls ($P_{adj} < 0.05$). D) Volcano plot to show monocyte expressed transcripts associated with baseline peripheral monocyte count (DESEq2 analysis, controlling for age and sex, 88 C1

496 samples, $P_{adj} < 0.05$). E) Scatterplot to show correlation between monocyte expression of FAM202

- 497 and IMPDH2 and peripheral monocyte count at baseline (C1) (Pearson's correlation).
- 498

499 Figure 2: Transcriptional responses to ICB in circulating monocytes

- Volcano plot to show differentially regulated transcripts in response to: A) ICB across cICB and 500 sICB treated patients (DESEq2 controlling for age, sex and treatment type (sICB or cICB), n = 96501 patients, $P_{adi} < 0.05$) and B) cICB (DESEq2 pairwise analysis, 51 patients). C) Barplot to show 502 number of induced/suppressed transcripts with ICB (Both sICB and cICB treated patients, n = 96503 patients, sICB n=45 patients and cICB n=51 patients). D) Dot plots to show key significantly 504 505 enriched GOBP pathways induced and suppressed with ICB across all patients ($P_{adj} < 0.05$). E) 506 Plot to show correlation between log₂ fold change (FC) of transcripts significantly differentially 507 expressed with cICB ('log2FC cICB') versus the log₂ fold change of those same transcripts following sICB ('log2FC sICB') (Pearson's correlation). F) Dot plot to show key preferentially 508 enriched GOBP pathways with cICB versus sICB ($P_{adj} < 0.05$). 509
- 510

511 Figure 3: Transcriptional correlates of clinical response in peripheral monocytes

Volcano plot to show transcripts associated with death at: A) three months; B) six months and C) twelve months after the date of commencing of the first cycle of ICB treatment (DESeq2 analysis, controlling for age, sex, treatment status and treatment type, 114 C1 patients, 98 C2 patients, P_{adj} <0.05). D) Volcano plot to show transcripts associated with disease progression at six months (DESeq2 analysis, controlling for age, sex, treatment status and treatment type, 113 C1 patients, 98 C2 patients, P_{adj} <0.05). E) Dot plot to show selected GOBP pathways enriched across transcripts associated with risk of death at three months (P_{adj} <0.05).

519

520 Figure 4: Monocyte heterogeneity and immune checkpoint blockade responses

A)Boxplots to show monocyte subsets (classical, intermediate and non-classical) as a proportion 521 of the total peripheral monocyte population as assessed by flow cytometry across 53 paired C1 522 523 and C2 patient samples (paired Wilcoxon signed-rank test). Points are coloured by treatment type (cICB = red, sICB = blue). B) Kaplan-Meier curve to show non-classical monocyte subset size as 524 a proportion of monocyte population above/below median) and overall survival (OS) (C1, n=57, 525 C2, n=59) and progression free survival (PFS) (57 C1, 59 C2 samples) (log-rank test). C) Kaplan-526 Meier curve to show total monocyte subset size as a proportion of all PBMCs on flow cytometry 527 above/below median) and OS at baseline at C1 (n = 57 patients, log-rank tests), and C2 (n=59528 529 patients, log-rank test) and progression free survival (PFS) at C2 (n = 59, log-rank test).

530

531 Figure 5: Characterising monocyte subsets in the context of immune checkpoint blockade

A) (Left) UMAP plot to show monocytes from eight patients receiving ICB at baseline (C1, d0) and 532 at d21 post-treatment (C2), plus three healthy donors) and Classical clusters 1-4 and CD16+ 533 monocytes (total cells n=22,116). (Right) UMAP plot to show monocytes coloured according to 534 classical and CD16⁺ cluster annotation assignment. B) Expression heatmap showing gene 535 expression profiles for Classical1, Classical2, Classical3, Classical4 and CD16⁺ monocytes 536 groups. Genes were selected to include the ten genes per classical group with the greatest log2 fold 537 change. C) Dotplot to show key GOBP pathways enriched in Classical1-4 and CD16⁺ monocyte 538 groups. D) Gene expression module score for each monocyte subgroup. Score is average of 539 expression of top 50 subgroup-defining genes for each monocyte subgroup. Positive value infers 540 541 expression is higher than expected, and negative value lower. F) Kaplan-Meier curve to show Classical4 expression score in bulk RNA-seq data above/below median expression score) at C1 and 542 OS (n = 113 patients, log-rank test) and PFS (n = 113 patients, log-rank test). 543

544

545 Supplementary Figure 1: Differentially expressed transcripts with sICB

- 546 Volcano plot to show differentially regulated transcripts in response to sICB (DESEq2 pairwise
- 547 *analysis*, 45 *patients*).
- 548
- 549 Supplementary Figure 2: Transcriptional correlates of clinical response in peripheral 550 monocytes from patients at baseline
- 551 Volcano plots to show transcript expression at baseline before treatment (C1) associated with
- death at: A) three months; B) six months and C) twelve months after the date of commencement of
- first cycle of ICB treatment (DESeq2 analysis, controlling for age, sex, and treatment type, 114

554 *C1 patients*, $P_{adj} < 0.05$).

555

556 Supplementary Figure 3: Monocyte subsets and response to ICB

- 557 Boxplots to show change in monocyte subset proportion with: A) cICB (n=29 paired patient
- samples) and B) sICB (n= 24 paired patient samples) (Paired Kruskal Wallis test). C) Kaplan
- 559 *Meier curve to show lymphocyte to monocyte ratio as per flow cytometry above/below median)*
- 560 before treatment, C1, and overall survival (OS) (n = 57 patients) (log-rank test).
- 561

562 Supplementary Figure 4: Single cell RNA-seq cohort details

563

564 Supplementary Figure 5: scRNA-seq clustering and annotation

- 565 A) UMAP plot to show all monocytes (from eight patients receiving ICB at baseline (C1) and day
- 566 21 post-treatment (C2), plus three healthy donor individuals ('C') clustered into nine subsets
- indicated by different colours (total cells n = 24,457) at resolution 0.25 with 13 dimensions. B)
- 568 Heatmap to show proportion of assigned cell types according to SingleR annotation using

expression sets including the Human Primary Cell Atlas, Monaco Immune, Immune Cell 569 570 Expression and Villani datasets. SingleR was used to compare the expression of each single cell to that of an annotated expression set providing classification annotation. Only cell type 571 572 annotations comprising at least 1% of the total scRNA-seq population were included. Scale ('mat') indicates proportion of cells in the subset assigned to that cell type with 1 indicating 100%. C) 573 UMAP plot to show Seurat subset assignment by patient ID.. 'C' denotes control samples 574 (comprises cells from three pooled healthy donor samples). Each point represents a cell and cells 575 are coloured by Seurat cluster assignment. D) Table to show summary of annotation of Seurat 576 monocytes clusters (Seurat clusters 0-8) with SingleR. 577

579 samples. Patient ID7 was removed completely from comparisons between C1 and C2 monocyte 580 subgroup proportion sizes.

We removed subset 5 from downstream analysis as it was limited to patient ID7, and control

581

578

582 Supplementary Figure 6: Characterising monocyte subsets with scRNA-seq

A) Heatmap to show top 20 genes by log2 fold change in classical subset comprising all Classical

groups 1-4 merged (n = 21,276 cells) and CD16+ monocyte (n=840 cells) subgroups. B) Dotplot

to show GOBP pathways most significantly enriched (top 15 most significant pathways,

586 *Padj*<0.05) in classical and CD16+ monocyte subgroups.

587

588 Supplementary Figure 7: Table to show hub genes for gene expression module scoring in 589 scRNA-seq data.

590

591 Supplementary Figure 8: Monocyte population responses to ICB

592	A) Boxplots to show percentage of each monocyte group per sample both before (C1) and after
593	(C2) ICB (n=7 paired patient samples with patient ID7 removed). B) Barplot to show proportion
594	of monocyte subgroups by condition across all patients (At C1 n = 9000 cells, at C2 n =9082 cells).
595	C) Boxplot to show percentage per samples pre and post treatment by monocyte group for sICB
596	patients ($n=4$ paired patient samples). D) Boxplot to show percentage per samples pre and post
597	treatment by monocyte group for cICB patients ($n=3$ paired patient samples). E) Boxplot to show
598	percentage of classical and CD16+ monocytes per patient sample ($n=7$ paired patient samples).

- 599 Significance performed by a paired Wilcoxon signed rank test.
- 600
- 601
- Table 1: Differentially expressed genes in MM patients versus healthy donors.
- Table 2: GOBP pathways enriched comparing MM versus healthy donors.
- 604 **Table 3:** Baseline monocyte count associated expressed transcripts
- **Table 4:** monocyte count associated GOBP pathways
- Table 5: Differentially expressed transcripts in circulating monocytes in response to ICB at day
- 607 21 (C2) across both cICB and sICB patients.
- 608 **Table 6:** cICB associated differentially expressed transcripts
- 609 **Table 7:** sICB associated differentially expressed transcripts
- 610 **Table 8:** GOBP pathways enriched across induced and suppressed transcripts following ICB at
- 611 day 21 (C2).
- Table 9: Differentially expressed transcripts preferentially induced at day 21 (C2) in those
 receiving cICB versus sICB.
- Table 10: GOBP pathways enriched across transcripts preferentially induced in response to cICB
 versus sICB.

- Table 11: Transcripts differentially associated with death at three months after starting ICB
 (C1&C2, sICB and cICB).
- Table 12: Transcripts differentially associated with death at six months after starting ICB
- (C1&C2, sICB and cICB).
- 620 **Table 13:** Transcripts differentially associated with death at twelve months after starting ICB
- (C1&C2, sICB and cICB).
- 622 **Table 14:** GOBP pathways enriched across transcripts associated with death at three months after
- starting ICB (C1&C2, sICB and cICB).

Table 15: GOBP pathways enriched across transcripts associated with death at six months after

- starting ICB (C1&C2, sICB and cICB).
- Table 16: GOBP pathways enriched across transcripts associated with death at twelve months
- after starting ICB (C1&C2, sICB and cICB).
- Table 17A: Transcripts differentially associated with death at three months after starting ICB (C1
- 629 pre-treatment only, sICB and cICB).
- **Table 17B:** Transcripts differentially associated with death at six months after starting ICB (C1
- 631 pre-treatment only, sICB and cICB).
- **Table 17C:** Transcripts differentially associated with death at twelve months after starting ICB
- 633 (C1 pre-treatment only, sICB and cICB).
- Table 18A: Transcripts differentially associated with six month progression (C1&C2, sICB andcICB).
- Table 18B: GOBP pathways enriched across transcripts associated with disease progression
 within six months of starting ICB (C1&C2, sICB and cICB).
- Table 19: Transcripts defining monocyte subgroups (Classical1, Classical2, Classical3,
 Classical4, CD16+ monocytes).

640 **Table 20:** Transcripts defining classical monocytes versus CD16+ monocytes with scRNA-seq.
 Table 21: GOBP pathways enriched across transcripts defining monocyte subgroups (Classical 1 641 642 4, CD16+ monocytes) 643 **Table 22:** GOBP pathways enriched across transcripts defining merged large classical group and 644 CD16+ monocytes. Tables 23-28: to show cohort details for scRNA-seq data and significantly correlated genes across 645 scRNA-seq data with hub gene (pearson's correlation, adjusted for multiple testing). 646 647 **Author contributions** 648 BPF conceived and oversaw the study. MPF, RAW, WY, MM recruited patients. RAW annotated 649 clinical outcome data. RAC, CT, RAW, OT, AVA, PKS, EM, SD and SK collected patient samples 650 and isolated CD14+ cells. RAC and RAW performed the scRNA-seq experiments. CT, OT, EM 651 and AVA performed bulk RNA-seq experiments. IN performed bioinformatic pre-processing of 652 653 bulk RNA-seq and scRNA-seq data. CAT performed flow cytometry experiments. RAC performed 654 computational analysis of the bulk RNA-seq, scRNA-seq and flow cytometry data. RAC produced figures and RAC and BPF drafted the manuscript. 655

656

657 Acknowledgments and Funding

We acknowledge and thank all the patients who donated material for this study. We thank the teams at the Day Treatment Unit at the Oxford Cancer Centre for facilitating this study.

660 This work was funded by a Wellcome Trust Intermediate Clinical fellowship held by BPF (no.

661 201488/Z/16/Z), which also supported IN, SD and AVA. RAC was funded by CRUK Clinical

662 Research Training Fellowship (S_3578). CAT was funded by the Engineering and Physical

663 Sciences Research Council and Balliol Jowett Society (no. D4T00070). RAW was funded by a

Wellcome Trust Doctoral Training Fellowship (no. BST00070). OT was funded by the Clarendon 664 Fund, Oxford Australia Fellowship and St Edmund's Hall. WY was supported by an NIHR ACF 665 and a CRUK Predoctoral Fellowship (ref. RCCTI100019). MM and BPF are supported by the 666 NIHR Oxford Biomedical Research Centre. 667 668 669 670 671 References 672 673 674 1. Larkin, J. et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine 381, 1535–1546 (2019). 675 676 2. Hodi, F. S. et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced 677 melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 19, 678 1480-1492 (2018). Ye, W. et al. Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic 679 3. melanoma and distinct T-cell expression profiles. Br J Cancer 1-9 (2021) doi:10.1038/s41416-021-01310-3. 680 4. Fairfax, B. P. et al. Peripheral CD8+ T cell characteristics associated with durable responses to immune 681 682 checkpoint blockade in patients with metastatic melanoma. Nature Medicine vol. 26 193-199 Preprint at 683 https://doi.org/10.1038/s41591-019-0734-6 (2020). 684 5. Watson, R. A. et al. Immune checkpoint blockade sensitivity and progression-free survival associates with 685 baseline CD8+ T cell clone size and cytotoxicity. Sci Immunol 6, (2021). 686 6. Chasseuil, E. et al. Blood predictive biomarkers for nivolumab in advanced melanoma. Acta Derm Venereol 687 98, 406–410 (2018). 688 7. Soyano, A. E. et al. Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung 689 Cancer patients treated with anti-PD-1 antibodies. J Immunother Cancer 6, 129 (2018). 690 8. Ziegler-Heitbrock, L. et al. Nomenclature of monocytes and dendritic cells in blood. Blood vol. 116 Preprint 691 at https://doi.org/10.1182/blood-2010-02-258558 (2010). 692 9. Krieg, C. et al. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat 693 Med 24, 144–153 (2018). 694 10. Romano, E. et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U S A 112, 6140-6145 (2015). 695 11. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data 696 697 with DESeq2. Genome Biol 15, (2014). 698 12. Schalper, K. A. et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and 699 reduced clinical benefit of immune-checkpoint inhibitors. Nat Med 26, 688-692 (2020). 700 Ashburner, M. et al. Gene ontology: Tool for the unification of biology. Nature Genetics vol. 25 25-29 13. 701 Preprint at https://doi.org/10.1038/75556 (2000). 702 14. Nalbant, D. et al. FAM20: an evolutionarily conserved family of secreted proteins expressed in 703 hematopoietic cells. BMC Genomics 6, 11 (2005). 704 15. Karigane, D. et al. p38a Activates Purine Metabolism to Initiate Hematopoietic Stem/Progenitor Cell 705 Cycling in Response to Stress. Cell Stem Cell 19, 192-204 (2016).

706	16.	Metzemaekers, M., Vanheule, V., Janssens, R., Struyf, S. & Proost, P. Overview of the mechanisms that
707		may contribute to the non-redundant activities of interferon-inducible CXC chemokine receptor 3 ligands.
708		Frontiers in Immunology vol. 8 1970 Preprint at https://doi.org/10.3389/fimmu.2017.01970 (2018).
709	17.	Tokunaga, R. et al. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel
710		cancer therapy. <i>Cancer Treatment Reviews</i> vol. 63 40–47 Preprint at
711	10	https://doi.org/10.1016/j.ctrv.2017.11.007 (2018).
712	18.	Khan, S. <i>et al.</i> Immune dysregulation in cancer patients developing immune-related adverse events. <i>Br J</i>
713 714	19.	<i>Cancer</i> 120 , 63–68 (2019). Nuñez, N. G. <i>et al.</i> Immune signatures predict development of autoimmune toxicity in patients with cancer
714	19.	treated with immune checkpoint inhibitors. <i>Med</i> 4 , 113-129.e7 (2023).
715	20.	Chen, S. <i>et al.</i> Mechanisms regulating PD-L1 expression on tumor and immune cells. <i>J Immunother Cancer</i>
717	20.	7, 1–12 (2019).
718	21.	Zerdes, I., Matikas, A., Bergh, J., Rassidakis, G. Z. & Foukakis, T. Genetic, transcriptional and post-
719		translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical
720		correlations. <i>Oncogene</i> vol. 37 4639–4661 Preprint at https://doi.org/10.1038/s41388-018-0303-3 (2018).
721	22.	Ragland, S. A. & Criss, A. K. From bacterial killing to immune modulation: Recent insights into the
722		functions of lysozyme. PLoS Pathog 13, e1006512 (2017).
723	23.	Yeap, W. H. et al. CD16 is indispensable for antibodydependent cellular cytotoxicity by human monocytes.
724		<i>Sci Rep</i> 6 , 1–22 (2016).
725	24.	Kapellos, T. S. et al. Human monocyte subsets and phenotypes in major chronic inflammatory diseases.
726		Frontiers in Immunology vol. 10 2035 Preprint at https://doi.org/10.3389/fimmu.2019.02035 (2019).
727	25.	Wan, L., Wu, C., Luo, S. & Xie, X. Prognostic Value of Lymphocyte-to-Monocyte Ratio (LMR) in Cancer
728		Patients Undergoing Immune Checkpoint Inhibitors. Dis Markers 2022, (2022).
729	26.	Wu, Q., Tu, H. & Li, J. Multifaceted Roles of Chemokine C-X-C Motif Ligand 7 in Inflammatory Diseases
730		and Cancer. Front Pharmacol 13, (2022).
731	27.	Geng, H., Xu, G., Ran, Y., López, J. A. & Peng, Y. Platelet Glycoprotein Ibβ/IX Mediates Glycoprotein Ibα
732		Localization to Membrane Lipid Domain Critical for von Willebrand Factor Interaction at High Shear. J
733	20	Biol Chem 286, 21315 (2011).
734 735	28.	Trizzino, M. <i>et al.</i> EGR1 is a gatekeeper of inflammatory enhancers in human macrophages. <i>Sci Adv</i> 7 , (2021).
736	29.	Gren, S. T. <i>et al.</i> A Single-Cell Gene-Expression Profile Reveals Inter-Cellular Heterogeneity within Human
737	29.	Monocyte Subsets. <i>PLoS One</i> 10 , e0144351 (2015).
738	30.	Wight, T. N. <i>et al.</i> Versican—A Critical Extracellular Matrix Regulator of Immunity and Inflammation.
739	50.	Front Immunol 0 , 512 (2020).
740	31.	Tsou, C. L. et al. Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and
741		recruitment to inflammatory sites. Journal of Clinical Investigation 117, 902–909 (2007).
742	32.	Cassetta, L. et al. Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal
743		Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets. Cancer Cell 35, 588-602.e10
744		(2019).
745	33.	Ramos, R. N. et al. CD163 + tumor-associated macrophage accumulation in breast cancer patients reflects
746		both local differentiation signals and systemic skewing of monocytes. Clin Transl Immunology 9, (2020).
747	34.	Qian, B. Z. et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475,
748		222–225 (2011).
749	35.	Ugurel, S. <i>et al.</i> Down-regulation of HLA II and costimulatory CD86/B7-2 on circulating monocytes from
750	26	melanoma patients. <i>Cancer Immunology, Immunotherapy</i> 53 , 551–559 (2004).
751	36.	Gordon, I. O. & Freedman, R. S. Defective antitumor function of monocyte-derived macrophages from
752	27	epithelial ovarian cancer patients. <i>Clinical Cancer Research</i> 12 , 1515–1524 (2006).
753 754	37.	Almand, B. <i>et al.</i> Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer. <i>The Journal of Immunology</i> 166 , 678–689 (2001).
754 755	38.	Lee, Y. Y. <i>et al.</i> Prognostic value of pre-treatment circulating monocyte count in patients with cervical
756	56.	cancer: Comparison with SCC-Ag level. <i>Gynecol Oncol</i> 124 , 92–97 (2012).
757	39.	Machida, H. <i>et al.</i> Significance of Monocyte Counts at Recurrence on Survival Outcome of Women With
758	57.	Endometrial Cancer. International Journal of Gynecologic Cancer 27, 302–310 (2017).
759	40.	Hayashi, T. <i>et al.</i> Peripheral blood monocyte count reflecting tumor-infiltrating macrophages is a predictive
760		factor of adverse pathology in radical prostatectomy specimens. <i>Prostate</i> 77 , 1383–1388 (2017).
761	41.	Wen, S. <i>et al.</i> Elevated peripheral absolute monocyte count related to clinicopathological features and poor
762		prognosis in solid tumors: Systematic review, meta-analysis, and meta-regression. <i>Cancer Med</i> 10 , 1690
763		(2021).

Chow, M. T. et al. Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-

42.


PD-1 therapy. Immunity 50, 1498 (2019).

764


765

House, I. G. et al. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses 766 43. following immune checkpoint blockade. Clinical Cancer Research 26, 487–504 (2020). 767 768 44. Wen, J. et al. Prognostic significance of preoperative circulating monocyte count in patients with breast 769 cancer based on a large cohort study. Medicine (United States) 94, (2015). 770 Wen, S. et al. Peripheral monocyte counts predict the clinical outcome for patients with colorectal cancer. 45. 771 Eur J Gastroenterol Hepatol 31, 1 (2019). 772 Gebhardt, C. et al. Myeloid cells and related chronic inflammatory factors as novel predictive markers in 46. 773 melanoma treatment with ipilimumab. Clinical Cancer Research 21, 5453-5459 (2015). 774 47. Kiss, M., Caro, A. A., Raes, G. & Laoui, D. Systemic Reprogramming of Monocytes in Cancer. Frontiers in 775 Oncology vol. 10 1399 Preprint at https://doi.org/10.3389/fonc.2020.01399 (2020). 776 48. Villani, A. C. et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and 777 progenitors. Science (1979) 356, (2017). 778 49. Goudot, C. et al. Aryl Hydrocarbon Receptor Controls Monocyte Differentiation into Dendritic Cells versus 779 Macrophages. Immunity 47, 582-596.e6 (2017). 780 50. Vishwakarma, A. et al. Title: Mapping the Immune Landscape of Clear Cell Renal Cell Carcinoma by 781 Single-Cell RNA-seq. doi:10.1101/824482. 782 51. Zilionis, R. et al. Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved 783 Myeloid Populations across Individuals and Species. Immunity 50, 1317-1334.e10 (2019). 784 52. Allen, N. et al. Circulating monocyte-platelet aggregates are a robust marker of platelet activity in 785 cardiovascular disease. Atherosclerosis 282, 11-18 (2019). 786 53. Hottz, E. D. et al. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor 787 expression in patients with severe COVID-19. Blood 136, 1330-1341 (2020). 54. 788 Passacquale, G. et al. Monocyte-Platelet Interaction Induces a Pro-Inflammatory Phenotype in Circulating 789 Monocytes. PLoS One 6, e25595 (2011). 790 Kim, D., Langmead, B. & Salzberg, S. L. HISAT: A fast spliced aligner with low memory requirements. 55. 791 Nat Methods 12, 357–360 (2015). 792 56. Anders, S., Pyl, P. T. & Huber, W. HTSeq—a Python framework to work with high-throughput sequencing 793 data. *Bioinformatics* **31**, 166 (2015). 794 Zhang, Y., Parmigiani, G. & Johnson, W. E. ComBat-seq: batch effect adjustment for RNA-seq count data. 57. 795 NAR Genom Bioinform 2, (2020). 796 58. Fang, H., Knezevic, B., Burnham, K. L. & Knight, J. C. XGR software for enhanced interpretation of 797 genomic summary data, illustrated by application to immunological traits. Genome Med 8, 129 (2016). 798 59. Chromium Single Cell V(D)J Reagent Kits User Guide (v1.1 Chemistry) with Feature Barcoding technology 799 for Cell Surface Protein -User Guide -Index -Single Cell Immune Profiling -Official 10x Genomics Support. 800 https://support.10xgenomics.com/single-cell-vdj/index/doc/user-guide-chromium-single-cell-vdj-reagent-801 kits-user-guide-v11-chemistry-with-feature-barcoding-technology-for-cell-surface-protein. 802 60. Release Notes for Cell Ranger 3.0 Gene Expression & Feature Barcoding -Software -Single Cell Gene 803 Expression -Official 10x Genomics Support. https://support.10xgenomics.com/single-cell-gene-804 expression/software/release-notes/3-0. 805 61. Package 'scater' Title Single-Cell Analysis Toolkit for Gene Expression Data in R Description A collection of tools for doing various analyses of single-cell RNA-seq gene expression data, with a focus on quality 806 807 control and visualization. (2021). Lun, A. T. L., McCarthy, D. J. & Marioni, J. C. A step-by-step workflow for low-level analysis of single-808 62. 809 cell RNA-seq data with Bioconductor. F1000Res 5, (2016). 810 63. Butler, A. & Satija, R. Integrated analysis of single cell transcriptomic data across conditions, technologies, 811 and species. bioRxiv 164889 Preprint at https://doi.org/10.1101/164889 (2017). 812 64. Zappia, L. & Oshlack, A. Clustering trees: a visualization for evaluating clusterings at multiple resolutions. 813 *Gigascience* **7**, 1–9 (2018). Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic 814 65. 815 macrophage. Nat Immunol 20, 163-172 (2019). 816 66. Mabbott, N. A., Baillie, J. K., Brown, H., Freeman, T. C. & Hume, D. A. An expression atlas of human 817 primary cells: Inference of gene function from coexpression networks. BMC Genomics 14, 632 (2013). 818 67. Monaco, G. et al. RNA-Seq Signatures Normalized by mRNA Abundance Allow Absolute Deconvolution of Human Immune Cell Types. Cell Rep 26, 1627-1640.e7 (2019). 819

- Schmiedel, B. J. et al. Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression. Cell 175, 1701-
- 821 1715.e16 (2018).








Ε

response


o none


induced

suppressed












F

С



В








Α

-log10(adjusted p-value)


10






















С



Α



Expression

a

Chemotaxis

Antigen presentation

-

÷

õ

Non-classical

IFN signalling

Cla

 $\overline{\mathbf{O}}$

Sa

õ

